Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Athenex Announces Abstracts Accepted for Presentation at the 2019 American Society of Clinical Oncology Annual Meeting | ||
By: Nasdaq / GlobeNewswire - 23 Apr 2019 | Back to overview list |
|
BUFFALO, N.Y., April 23, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that four abstracts have been accepted for presentation at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 31 to June 4, 2019 at the McCormick Place Convention Center in Chicago, Illinois. “We are very pleased with the abstracts that have been accepted for presentation at ASCO this year,” said Dr. Johnson Lau, Chairman and Chief Executive Officer of Athenex. “We look forward to sharing additional information on our lead, pivotal stage Oraxol (Oral paclitaxel and HM30181A) program as well as preliminary results from our Oratecan (Oral irinotecan and HM30181A) Phase I study and preclinical proof of concept data for our new arginine deprivation therapy platform, Pegtomarginase. We believe these will demonstrate the broad applicability of the Orascovery technology for a wide range of commonly used chemotherapy agents and the depth of our oncology-focused pipeline.” Presentation details: Title: (Abstract TPS1116) KX-ORAX-001: An open label, randomized, multicenter, Phase III registrational study to determine the safety, tolerability, and tumor response of Oraxol (HM30181A + oral paclitaxel) and its comparability to IV paclitaxel in patients with metastatic breast cancer (MBC). Title: (Abstract 1084) Oral paclitaxel in the treatment of metastatic breast cancer (MBC) patients. Title: (Abstract 3032) A Phase 1 study of the oral administration of irinotecan in combination with the potent P-glycoprotein (P-gp) inhibitor HM30181A. Title: (Abstract 3090) Design, engineering, and characterization of a novel long-acting (Pegylated) single isomer human arginase for arginine depriving anti-cancer treatment. The abstract titles are currently available on the ASCO iPlanner website, with the full abstracts scheduled to be published on May 15, 2019. Athenex has received approval of the International Nonproprietary Name (INN) “encequidar” for its novel P-gp pump inhibitor molecule, HM30181A. The Company may use the nomenclature “encequidar” in future communications. The Orascovery platform was initially developed by Hanmi Pharmaceuticals and licensed exclusively to Athenex for all major worldwide territories except Korea, which is retained by Hanmi. About Athenex, Inc. Forward-Looking Statement CONTACTS Investor Relations: Tim McCarthy Athenex, Inc.: Randoll Sze Jacqueline Li |
||
|
||
Copyright 2019 Nasdaq / GlobeNewswire | Back to overview list |